Marinus RAISE trial interim analysis fails early stopping criteria; Q1 ZTALMY revenue $7.4-7.6M

MARINUS PHARMACEUTICALS, INC.

DMC recommended continue RAISE; enrollment completed at ~100 patients; topline results summer 2024.
Q1 2024 preliminary ZTALMY net revenue $7.4-7.6 million; cash $113.3 million as of March 31.
TrustTSC enrollment expected mid-May; topline data on track for Q4 2024.
Cost reduction activities under review to extend cash runway beyond Q4 2024.
IV ganaxolone development for RSE to be reassessed after final RAISE results.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MARINUS PHARMACEUTICALS, INC. reported the quarter ended March 31, 2024 results: revenue between $7.4 and $7.6 million.

Period: the quarter ended March 31, 2024
Revenue: between $7.4 and $7.6 million
Result: preliminary results

Exact text from the filing

Cost reduction activities to extend cash runway are under review and expected to be implemented Q2 2024 ZTALMY ® (ganaxolone) Q1 2024 preliminary net product revenue of between $7.4 and $7.6 million; preliminary unaudited cash, cash equivalents and short-term investments of $113.3 million as of March 31, 2024 RADNOR, Pa. – April 15, 2024 – Marinus

View on SEC.gov

322 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-046976

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.